The deal is significantly higher than Pfizer’s original bid for Metsera in September.A Pfizer office in a file image. Johanna Geron/Reuters11/13/2025|Updated: 11/13/2025Pharmaceutical maker Pfizer announced on Nov. 13 that it had completed its $10 billion acquisition of Metsera, ending a convoluted bidding war for the clinical-stage obesity biotech company.Pfizer purchased all outstanding shares of Metsera stock at $65.60 per share, an enterprise valuation of about $7 billion, with additional contingent value right (CVR) payments of $20.65 per share that are tied to Metsera hitting certain clinical and regulatory milestones.Rob Sabo has worked as a business journalist for nearly two decades and covers a broad range of business topics for The Epoch Times.Author’s Selected Articles
15.5
C
Ottawa
Sunday, June 14, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS